抗心脑血管疾病药剂相关公司(国外英文资料).docVIP

抗心脑血管疾病药剂相关公司(国外英文资料) Anticardioascular disease agents One, antihypertensive drugs The calcium channel blockers in the Chinese market because of its can be applied to various degrees of hypertension, which is listed in the 1980 s, time to market early, high degree of doctors accept thus occupies the largest market share, as of June in 09 of the rolling years accounted for about 39.2%, the market share is the second angiotensin Ⅱ receptor antagonist, namely sand drugs, these drugs belong to the new drug, is the international mainstream products, produced in the field such as valsartan multiple blockbuster, efficacy of clear side effects are smaller, but the price is relatively high, occupy 28.7% of the share; Vascular beta beta beta transformation enzyme inhibitor, namely split drugs ranked third, these drugs listed earlier statins, sand, widely used clinically, share of about 13.5%. From the market growth of new drugs, this growth has been relatively high, in the past five years the average growth of 45%, growth in the second for diuretics, 09 June year-on-year growth of 31%, with 27% calcium channel blockers in third place. Sand jotham drugs or is expected to future growth at high speed, its side effect is less than the simplex drugs, antihypertensive effect is remarkable, very competitive, future market prospects look good, it is also consistent with the international market, we do focus on analysis of these drugs. Calcium channel blockers Of the top 20 cardiovascular drugs in 2007, calcium antagonists had three finalists, accounting for 20.5 percent of sales. Amlodipine is one of the largest varieties of sales amount, but because of the price on the high side, did not become the best-selling domestic calcium antagonists, in amlodipine numerous manufacturer home, Pfizer pharmaceutical co., LTD., dalian collaterals live happy with 54.6% of the absolute advantage ahead of other manufacturers. Calcium channel blockers drug companies in the first generation of rank: P